Key points are not available for this paper at this time.
In first individual cases, iRIT with 177LuLu-6A10-Fab appears to be feasible and safe, without therapy-related side effects. A confirmatory multicenter phase-I-trial was recently opened and is currently recruiting.
Anna Uhl Chamot (Thu,) studied this question.